Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Gyre Therapeutics (GYRE) Receivables - Net (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Receivables - Net for 15 consecutive years, with $25.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables - Net rose 32.79% to $25.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.9 million, a 32.79% increase, with the full-year FY2024 number at $19.6 million, up 29.19% from a year prior.
  • Receivables - Net was $25.9 million for Q3 2025 at Gyre Therapeutics, up from $24.6 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $25.9 million in Q3 2025 to a low of $564000.0 in Q1 2022.
  • A 5-year average of $11.7 million and a median of $15.2 million in 2023 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: plummeted 45.13% in 2021, then surged 842.57% in 2022.
  • Gyre Therapeutics' Receivables - Net stood at $1.8 million in 2021, then soared by 842.57% to $17.1 million in 2022, then fell by 11.51% to $15.2 million in 2023, then increased by 29.19% to $19.6 million in 2024, then soared by 32.1% to $25.9 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Receivables - Net are $25.9 million (Q3 2025), $24.6 million (Q2 2025), and $22.3 million (Q1 2025).